1st Edition
Drug Repositioning Approaches and Applications for Neurotherapeutics
Section I The Rationale and Economics
of Drug Repositioning
Chapter 1 Scientific and Commercial Value of Drug Repurposing
David Cavalla
Chapter 2 Repurposing for Alzheimer’s and Parkinson’s Diseases: The
Ideas, the Pipeline, the Successes, and the Disappointments
Hermann Mucke
Chapter 3 Contribution of Not-for-Profit Organizations to Drug Repurposing
Bruce Bloom
Section II Repositioning Approaches and
Technologies: From Serendipity to
Systematic and Rational Strategies
Chapter 4 Systematic Drug Repositioning
Spyros N. Deftereos, Aris Persidis, Andreas Persidis,
Eftychia Lekka, Christos Andronis, and Vassilis Virvillis
Chapter 5 Technical Tools for Computational Drug Repositioning
Francesco Napolitano
Chapter 6 RNAi Screening toward Therapeutic Drug Repurposing
Nichole Orr-Burks, Byoung-Shik Shim, Olivia Perwitasari,
and Ralph A. Tripp
Chapter 7 Phenotypic Screening
Christine M. Macolino-Kane, John R. Ciallella,
Christopher A. Lipinski, and Andrew G. Reaume
Section III Drug Repositioning for
Nervous System Diseases
Chapter 8 A Case Study: Chlorpromazine
Francisco López-Munoz, Cecilio Álamo,
and Silvia E. García-Ramos
Chapter 9 Drug Repurposing for Central Nervous System Disorders: A
Pillar of New Drug Discovery
Mondher Toumi, Aleksandra Caban, Anna Kapuśniak,
Szymon Jarosławski, and Cecile Rémuzat
Chapter 10 Repurposing Opportunities for Parkinson’s Disease Therapies
Giulia Ambrosi, Silvia Cerri, and Fabio Blandini
Chapter 11 Drug Candidates for Repositioning in Alzheimer’s Disease
Maria P. del Castillo-Frias and Andrew J. Doig
Biography
Dr. Joel Dudley is associate professor of genetics and genomic sciences and director of biomedical informatics at Mount Sinai School of Medicine, New York (NY, USA).
Dr. Laura Berliocchi is associate professor of pharmacology at the Department of Health Sciences, Magna Graecia University (Catanzaro, Italy).
This excellent book is a must read for those interested in drug-repositioning and those involved in the hunt for new effective neurotherapeutics. The introductory sections of the book provide not only a clear explanation of the merits of repositioning but also an honest consideration of the difficulties of the approach. This is well illustrated by examples from the fields of Alzheimer’s and Parkinson’s describing successes and failures. Also introduced is the value of drug-repositioning to not-for profit organisations. Which adds to those who are involved in medical charity research to list of those who should read this publication. For the reader whose interest is piqued by the possibilities of drug repositioning and want to know more of the mechanics following chapters explore a variety of techniques that can be adopted for the identification of candidate repositioned therapies. Again, these an honest consideration with both pro and cons described. This makes the publication useful reading for any interested in repositioning irrespective of their field of interest.
The latter sections focus on repositioning for a very diverse range of CNS conditions. These include Parkinson’s, Alzheimer’s, Huntingdon’s, ALS, Spinal muscular atrophy and Ischaemic injury. For those with specific interests in any of the above this is a useful work. But in addition, I would recommend to those with a specific CNS disease interest reading the other chapters as they provide a potentially useful insight into methods and approaches than could be adopted within a specific interest.
Taken together this is valuable read and reference work for a diverse readership.- Dr Alan Rothaul, Re-Pharm
Drug repositioning, also known as repurposing, seems an easy and straight forward route for the successful development of drugs. However, aspects of value creation and sound business cases are still essential, eve
